Partnering expands the range of services JSW and Affinity can offer to clients. Furthermore, the alliance represents a geographic expansion as JSW is based in Austria and Affinity’s headquarters is in Milford, New Hampshire, US.
JSW also has an office in Zagreb, Croatia. From this location JSW supports clinical trials in Eastern Europe, notably in Croatia, Slovenia, Bosnia and Herzegovina, Serbia and Macedonia.
Commenting on the geographic expansion, Manfred Windisch, president of JSW, said the deal allows the company “to further serve our North American and European clients”.
Windisch added that partnering will provide JSW’s clients “with additional biomarker assay development and good manufacturing practice (GMP) production services in support of drug development”.
Furthermore, Affinity, a contract manufacturing organisation (CMO), will provide JSW’s clients with immunoassay design, cell culture services and antibody purification and conjugation services.
In return Affinity’s clients will have access to a range of in vitro and in vivo services, including transgenic mouse models, offered by JSW, a neuroscience contract research organisation (CRO).
The deal with Affinity is the third partnership JSW has entered into. Through an alliance with HM Pharma Consultancy, which has offices in Vienna, Austria and Salt Lake City, Utah, US, it can offer clients assistance with patenting and intellectual property management.
JSW also has an established relationship with vuGene, a company offering direct to consumer genetic testing for mental and neurological conditions.